La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Mesoblast a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Mesoblast..

Mesoblast (NASDAQ:MESO) Azioni, Catena delle Opzioni

Mesoblast

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Limited - American Depositary Shares

Mesoblast Ltd

Meso Numismatics Inc

<p>Keybanc  analyst Philip Gibbs   maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Overweight and lowers the price target from $85 to $65.</p>


News

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Block, Lowers Price Target to $65

<h4>https://cloud.google.com/blog/topics/public-sector/google-public-sector-and-palantir-collaborate-to-bring-google-cloud-to-fedstart/</h4>
<h4>Palantir FedStart to launch on Google Cloud, empowering Anthropic and other Independent Software Vendors</h4>
<p>Google Cloud Next</p>
<p>On-demand access to Next's top highlights.</p>
<p><a href="https://cloud.withgoogle.com/next/25?utm_source=cgc-blog&amp;utm_medium=blog&amp;utm_campaign=FY25-Q2-global-EXP106-physicalevent-er-next25-mc&amp;utm_content=cgc-blog-left-hand-rail-post-next&amp;utm_term=-">Watch now</a></p>
<p>At Google Public Sector, we are committed to helping our customers execute their missions. Now, we're expanding this commitment by adding support for Palantir's FedStart platform, so public sector customers can utilize software and applications on Google Cloud's accredited infrastructure through the Palantir <a href="https://www.palantir.com/offerings/fedstart/">FedStart</a> platform.</p>
<p>Palantir FedStart helps U.S. government agencies achieve compliance, scale operations, and access innovative mission-critical solutions from leading independent software vendors (ISVs), including many built natively on Google Cloud. The combination of world-class solutions, Google's global-scale infrastructure and security, and Palantir's turnkey compliance will accelerate innovation across U.S. government agencies. This will provide government agencies with certified solutions across multiple cloud platforms, while upholding the highest security and compliance standards.</p>
<p>Our collaboration with Palantir also gives ISVs a faster path to accreditation and impact. At launch, the first ISV to use this new capability is Anthropic. Its <a href="https://www.anthropic.com/enterprise">Claude for Enterprise</a> application <a href="https://investors.palantir.com/news-details/2025/Anthropic-Joins-Palantirs-FedStart-Program-to-Deploy-Claude-Application/">will be available</a> to federal government agencies through Palantir FedStart on Google Cloud.</p>
<p>By partnering with industry leaders to bring cutting-edge technologies to the U.S. government, Google can accelerate public sector mission impact and outcomes. Key benefits of this offering include:</p>
<ul>
<li><strong>Accelerated ISV onboarding:</strong> Palantir's FedStart solution will streamline the FedRAMP High and IL5 accreditation process for ISVs built on Google Cloud.</li>
<li><strong>Enhanced AI capabilities:</strong> In addition to Gemini on Google Cloud, government customers will gain access to Anthropic's Claude for Enterprise and Palantir's technologies that back the FedStart offering on Google Cloud - including Apollo, Rubix, Foundry, and AIP.</li>
<li><strong>Secure and scalable infrastructure:</strong> Google Cloud's secure and scalable infrastructure will ensure the reliable and responsible deployment of AI solutions for sensitive government use cases, as opposed to the inherent limitations of legacy GovClouds. To thrive in this AI-driven era, our public sector customers need a modern cloud partner offering unmatched scale, features, and security that GovClouds cannot deliver, which is why <a href="https://cloud.google.com/blog/topics/public-sector/beyond-govclouds-building-a-secure-ai-enabled-government?e=48754805">we are committed to certifying our entire U.S. cloud infrastructure at IL5</a>.</li>
</ul>


GOOG

GOOGL

PLTR

Google Public Sector And Palantir Collaborate To Bring Google Cloud To FedStart

<p><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is up 7% on the day as a wave of whale activity and institutional interest boosts optimism for <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">a major breakout</a>.</p>
<p><strong>What Happened:</strong> Trader Tardigrade highlighted that DOGE/BTC has broken out of a descending trendline, suggesting DOGE may be preparing for a strong leg higher. </p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> is ready for a new surge &#x1f525;<a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a>/$BTC has just broken out of a descending trendline <a href="https://t.co/JymAFt8LD6">pic.twitter.com/JymAFt8LD6</a></p>
<p>&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1915002611255882026?ref_src=twsrc%5Etfw">April 23, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Trader &#8216;Investments_CEO&#8217; <a href="https://x.com/Investments_CEO/status/1914833791123689663">predicted</a> Dogecoin is "very close" to setting a new all-time high, citing rapidly rising smart money activity.</p>
<p>Nology <a href="https://x.com/nology3000/status/1914854408497848523">remains</a> bullish, though he admits he may have underestimated DOGE's full potential in a max bull scenario. </p>
<p>He's watching closely as price approaches a key resistance zone, what he calls the "big red bar", which may either confirm a breakout or reject the move.</p>
<p>Crypto chart analyst Ali Martinez observed DOGE breaking out of an ascending triangle pattern, with an upside target around $0.195.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> appears to be breaking out of an ascending triangle, with a potential upside target of $0.195! <a href="https://t.co/P7dkmIiQ9B">pic.twitter.com/P7dkmIiQ9B</a></p>
<p>&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1914742749892399213?ref_src=twsrc%5Etfw">April 22, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44870833/a-93-day-dogecoin-bull-spring-may-be-about-to-begin">A 93-Day Dogecoin Bull Spring May Be About To Begin</a></strong></p>
<p><strong>Why It Matters:</strong> 21Shares officially <a href="https://x.com/21Shares/status/1914979220767576113">launched</a> its Dogecoin exchange-traded product today, which has backing from the Dogecoin Foundation. </p>
<p>This marks a major milestone, providing regulated access to DOGE for traditional investors. </p>
<p>Whale activity has soared 900%, as large holders <a href="https://x.com/Investments_CEO/status/1914871612068741151">appear</a> to be accumulating and holding DOGE aggressively. </p>
<p>Coinglass data shows DOGE derivatives trading volume having expanded by 65.8% in single day, while open interest spiked 11.3% implying rising interest of traders. </p>
<p>Liquidations totaled $11.8 million, with shorts accounting for $8.8 million, indicating bearish traders were forced to exit as prices spiked.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44846673/meme-coin-market-is-very-much-alive-can-dogecoin-shiba-inu-fartcoin-bounce-back">Meme Coin Market Is &#8216;Very Much Alive&#8217;: Can Dogecoin, Shiba Inu, Fartcoin Bounce Back?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Dogecoin Jumps 7%, Whale Activity Surges 900%: What's Fueling The Rally?

<p>Keybanc  analyst Philip Gibbs   maintains Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) with a Overweight and lowers the price target from $140 to $105.</p>


SHOP

Keybanc Maintains Overweight on Shopify, Lowers Price Target to $105

<p>B. Riley Securities  analyst Hal Goetsch   reiterates Triumph Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) with a Neutral and lowers the price target from $65 to $55.</p>


Reiteration

TFIN

B. Riley Securities Reiterates Neutral on Triumph Financial, Lowers Price Target to $55

<p>Keybanc  analyst Philip Gibbs   maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and lowers the price target from $33 to $24.</p>


RELY

Keybanc Maintains Overweight on Remitly Global, Lowers Price Target to $24

<p>B. Riley Securities  analyst Nick Giles   reiterates Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) with a Buy and lowers the price target from $20 to $17.</p>


B. Riley Securities Reiterates Buy on Cleveland-Cliffs, Lowers Price Target to $17

<p>Shares of <strong>Lithia Motors </strong><span style="box-sizing: border-box; margin: 0px; padding: 0px;"><strong>Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a></span>AD) are trading lower in premarket on Wednesday after the company reported its first-quarter FY25 earnings.</p>
<p>The company reported first-quarter FY25 sales growth of 7.2% year-on-year to $9.18 billion, missing the analyst consensus estimate of $9.26 billion.</p>
<p>New vehicle, same-store units grew by 3.6%. New vehicle retail revenues increased 9.1% Y/Y, and used vehicle retail revenues climbed 4.2%.</p>
<p>Total vehicle gross profit per unit was $4,164. Gross profit rose 5.6% Y/Y to $1.41 billion, and the gross margin contracted 20 basis points to 15.4%.</p>
<p>Operating margin was 4.4%, and operating income for the quarter jumped 19% to $406.3 million.</p>
<p><strong>Also Read</strong>: <a href="https://www.benzinga.com/25/04/44938762/draftkings-may-trim-2025-forecast-amid-texas-jackpocket-shutdown-says-analyst">DraftKings May Trim 2025 Forecast Amid Texas Jackpocket Shutdown: Analyst</a></p>
<p>Adjusted EPS of $7.66 <a href="https://www.benzinga.com/earnings">missed the consensus </a>estimate of $7.69.</p>
<p>Lithia held $430.3 million in cash and equivalents as of the end of March. Operating cash flow for the quarter totaled $322.1 million.</p>
<p>Adjusted EBITDA increased 17.1% to $402.1 million. Net debt grew 1.8% Y/Y to $3.98 billion as of March-end.</p>
<p>The Board of Directors approved an increased dividend of&nbsp;$0.55&nbsp;per share related to first quarter 2025 financial results, a 4% increase. The dividend is expected to be paid on May&nbsp;23, 2025 to shareholders of record on May&nbsp;9, 2025.</p>
<p>During the first quarter 2025, we repurchased approximately 403,000 shares at a weighted average price of&nbsp;$326. Under the current share repurchase authorization approximately&nbsp;$669.2 million&nbsp;remains available.</p>
<p>"We achieved profitable growth year over year in each month this quarter as we grew market share and drove operating efficiencies across our network and adjacencies," said President and CEO Bryan DeBoer.</p>
<p><strong>Price Action</strong>: LAD shares traded lower by 3.96% at $283.82 in premarket at last check Wednesday.</p>
<p><strong>Read Next</strong>: <a href="https://www.benzinga.com/25/04/44936972/vertiv-nvidia-igenius-launch-ai-supercomputer-project-in-italy">Vertiv, NVIDIA, iGenius Launch AI Supercomputer Project In Italy</a></p>
<p><em>Photo: Shutterstock</em></p>


Earnings

General

Why Is Lithia Motors Stock Sliding Today?

<p>Scotiabank  analyst Maher Yaghi   maintains Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Sector Perform and raises the price target from $48.5 to $49.</p>


Scotiabank Maintains Sector Perform on Verizon Communications, Raises Price Target to $49

<p>Keybanc  analyst Michael Leshock   maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Overweight and lowers the price target from $75 to $55.</p>


HOOD

Keybanc Maintains Overweight on Robinhood Markets, Lowers Price Target to $55

Macro Economic Events

Econ #s

Economics

Reported Earlier: USA Gasoline Inventories 4.476M Barrel Draw Vs 1.958M	Barrel Draw Prior

<p>Keybanc  analyst Philip Gibbs   maintains Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) with a Overweight and lowers the price target from $145 to $80.</p>


Keybanc Maintains Overweight on Global Payments, Lowers Price Target to $80

Reported Earlier: EIA Weekly Distillates Stocks 2.353M Barrel Draw Vs 1.851M Barrel Draw Prior

<p>Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Dow to report an <strong>earnings per share</strong> (EPS) of $0.04.</p>
<p>Anticipation surrounds Dow's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed EPS by $0.24, which was followed by a 1.3% increase in the share price the next day.</p>
<p>Here's a look at Dow's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.24</td>
<td>0.46</td>
<td>0.71</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0</td>
<td>0.47</td>
<td>0.68</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-3.0%</td>
<td>0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745420668_0.png" alt="eps graph" /></p>
<h3>Performance of Dow Shares</h3>
<p>Shares of Dow were trading at $29.0 as of April 22. Over the last 52-week period, shares are down 46.92%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Perspectives on Dow</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Dow.</p>
<p>Analysts have given Dow a total of 14 ratings, with the consensus rating being Neutral. The average one-year price target is $37.86, indicating a potential 30.55% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Westlake, Cabot and Hawkins, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Westlake, with an average 1-year price target of $128.24, suggesting a potential 342.21% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Cabot, with an average 1-year price target of $84.0, suggesting a potential 189.66% upside.</li>
<li>Analysts currently favor an Buy trajectory for Hawkins, with an average 1-year price target of $141.0, suggesting a potential 386.21% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Westlake, Cabot and Hawkins, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dow</td>
<td>Neutral</td>
<td>-2.03%</td>
<td>$935M</td>
<td>-0.31%</td>
</tr>
<tr>
<td>Westlake</td>
<td>Buy</td>
<td>0.60%</td>
<td>$328M</td>
<td>0.07%</td>
</tr>
<tr>
<td>Cabot</td>
<td>Neutral</td>
<td>-0.31%</td>
<td>$235M</td>
<td>6.59%</td>
</tr>
<tr>
<td>Hawkins</td>
<td>Buy</td>
<td>8.49%</td>
<td>$48.42M</td>
<td>3.34%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Dow ranks at the bottom for Revenue Growth with a decrease of 2.03%. It also ranks lowest for Gross Profit at $935M. In terms of Return on Equity, Dow is at the bottom with a negative 0.31%.</p>
<h3>Get to Know Dow Better</h3>
<p>Dow Inc is a diversified chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a key producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets. The Company conducts its operations through six businesses, which are organized into segments, such as Packaging &amp; Specialty Plastics, Industrial Intermediates &amp;and Infrastructure and Performance Materials and Coatings. Packaging and Specialty.</p>
<h3>Breaking Down Dow's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Dow's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-2.03%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Dow's net margin is impressive, surpassing industry averages. With a net margin of <strong>-0.54%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dow's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-0.31%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Dow's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-0.1%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Dow's debt-to-equity ratio surpasses industry norms, standing at <strong>1.02</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/DOW/earnings"><strong>To track all earnings releases for Dow visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: Dow's Earnings Outlook

<p>West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) is preparing to release its quarterly earnings on Thursday, 2025-04-24. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect West Pharmaceutical Servs to report an <strong>earnings per share</strong> (EPS) of $1.23.</p>
<p>Anticipation surrounds West Pharmaceutical Servs's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.09, leading to a 7.84% increase in the share price the following trading session.</p>
<p>Here's a look at West Pharmaceutical Servs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.73</td>
<td>1.50</td>
<td>1.74</td>
<td>1.26</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.82</td>
<td>1.85</td>
<td>1.52</td>
<td>1.56</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>-7.000000000000001%</td>
<td>3.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745420659_0.png" alt="eps graph" /></p>
<h3>Tracking West Pharmaceutical Servs's Stock Performance</h3>
<p>Shares of West Pharmaceutical Servs were trading at $215.13 as of April 22. Over the last 52-week period, shares are down 40.19%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Views on West Pharmaceutical Servs</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on West Pharmaceutical Servs.</p>
<p>Analysts have provided West Pharmaceutical Servs with 2 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $300.0, suggesting a potential 39.45% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Illumina, Waters and Revvity, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Illumina, with an average 1-year price target of $129.4, suggesting a potential 39.85% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Waters, with an average 1-year price target of $406.7, suggesting a potential 89.05% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Revvity, with an average 1-year price target of $128.17, suggesting a potential 40.42% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Illumina, Waters and Revvity are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>West Pharmaceutical Servs</td>
<td>Outperform</td>
<td>2.30%</td>
<td>$273.60M</td>
<td>4.79%</td>
</tr>
<tr>
<td>Illumina</td>
<td>Neutral</td>
<td>-1.60%</td>
<td>$728M</td>
<td>8.31%</td>
</tr>
<tr>
<td>Waters</td>
<td>Neutral</td>
<td>6.50%</td>
<td>$524.20M</td>
<td>13.49%</td>
</tr>
<tr>
<td>Revvity</td>
<td>Outperform</td>
<td>4.81%</td>
<td>$412.29M</td>
<td>1.21%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>West Pharmaceutical Servs ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Discovering West Pharmaceutical Servs: A Closer Look</h3>
<p>West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.</p>
<h3>West Pharmaceutical Servs's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> West Pharmaceutical Servs's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>2.3%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> West Pharmaceutical Servs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>17.37%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> West Pharmaceutical Servs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.79%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> West Pharmaceutical Servs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.56%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> West Pharmaceutical Servs's debt-to-equity ratio is below the industry average. With a ratio of <b>0.11</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/WST/earnings"><strong>To track all earnings releases for West Pharmaceutical Servs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: West Pharmaceutical Servs's Quarterly Earnings

<p>Goldman Sachs  analyst Lizzie Dove   maintains Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Neutral and lowers the price target from $51 to $44.</p>


Goldman Sachs Maintains Neutral on Viking Holdings, Lowers Price Target to $44

<p>PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate PG&amp;E to report an <strong>earnings per share</strong> (EPS) of $0.40.</p>
<p>PG&amp;E bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.00, which was followed by a 3.53% drop in the share price the next day.</p>
<p>Here's a look at PG&amp;E's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.31</td>
<td>0.33</td>
<td>0.30</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.31</td>
<td>0.37</td>
<td>0.31</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>1.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745420647_0.png" alt="eps graph" /></p>
<h3>Tracking PG&amp;E's Stock Performance</h3>
<p>Shares of PG&amp;E were trading at $17.44 as of April 22. Over the last 52-week period, shares are up 2.72%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on PG&amp;E</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on PG&amp;E.</p>
<p>PG&amp;E has received a total of 9 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $20.78, the consensus suggests a potential 19.15% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Entergy, Xcel Energy and Exelon, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Entergy, with an average 1-year price target of $90.75, suggesting a potential 420.36% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Xcel Energy, with an average 1-year price target of $74.43, suggesting a potential 326.78% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Exelon, with an average 1-year price target of $47.0, suggesting a potential 169.5% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Entergy, Xcel Energy and Exelon, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PG&amp;E</td>
<td>Outperform</td>
<td>-5.82%</td>
<td>$2.19B</td>
<td>2.34%</td>
</tr>
<tr>
<td>Entergy</td>
<td>Outperform</td>
<td>0.64%</td>
<td>$1.25B</td>
<td>1.90%</td>
</tr>
<tr>
<td>Xcel Energy</td>
<td>Neutral</td>
<td>-9.35%</td>
<td>$1.29B</td>
<td>2.39%</td>
</tr>
<tr>
<td>Exelon</td>
<td>Neutral</td>
<td>1.94%</td>
<td>$2.39B</td>
<td>2.42%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>PG&amp;E ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is in the middle for Return on Equity.</p>
<h3>About PG&amp;E</h3>
<p>PG&amp;E is a holding company whose main subsidiary is Pacific Gas and Electric, a regulated utility operating in Central and Northern California that serves 5.3 million electricity customers and 4.6 million gas customers in 47 of the state's 58 counties. PG&amp;E operated under bankruptcy court supervision between January 2019 and June 2020. In 2004, PG&amp;E sold its unregulated assets as part of an earlier postbankruptcy reorganization.</p>
<h3>Breaking Down PG&amp;E's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining PG&amp;E's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-5.82%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> PG&amp;E's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>9.76%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> PG&amp;E's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>2.34%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> PG&amp;E's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.49%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.04</strong>, PG&amp;E faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/PCG/earnings"><strong>To track all earnings releases for PG&amp;E visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring PG&E's Earnings Expectations

<p><strong>International Business Machines </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) is likely to highlight its AI business segments, recent product launches and a new acquisition when the company reports its first-quarter financial results after the <a href="https://www.benzinga.com/earnings">market close Wednesday.</a></p>
<p>Here are the analyst estimates, analyst commentary and key items to watch ahead of the results.</p>
<p><strong>Earnings Estimates</strong>: Analysts expect IBM to report first-quarter revenue of $14.40 billion, down from $14.46 billion in last year's first quarter, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0423">from Benzinga Pro.</a></p>
<p>The company beat analyst revenue estimates in the fourth quarter and has beaten estimates in six of the last 10 quarters.</p>
<p>Analysts expect IBM to report first-quarter earnings per share of $1.40, down from $1.68 in last year's first quarter. The company has beaten analyst estimates for earnings per share in eight straight quarters and nine of the last 10 quarters overall.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/earnings/earnings-beats/25/01/43341886/ibm-posts-q4-earnings-beat-shifts-focus-to-software-as-analysts-raise-forecasts">IBM Posts Q4 Earnings Beat, Shifts Focus To Software As Analysts Raise Forecasts</a></strong></p>
<p><strong>What Experts Are Saying:</strong> Wedbush analyst Daniel Ives recently highlighted IBM as a company that could benefit from enterprise AI<a href="https://www.benzinga.com/25/03/44463025/software-companies-poised-for-gains-as-ai-spending-accelerates-says-analyst"> spending in 2025.</a></p>
<p>The analyst said IBM's cloud penetration has been successful and could represent a monetization opportunity for the company. IBM was added to the Wedbush Best Ideas List in March.</p>
<p>In February, Oppenheimer analyst Param Singh initiated coverage on IBM with an Outperform rating and a $320 price target.</p>
<p>The analyst said IBM can sustain double-digit revenue growth in its software business thanks to Red Hat. Singh said Red Hat has broadened its product offerings and could see high-teen to 20% growth.</p>
<p>Singh also highlighted IBM's potential in AI applications, such as generative AI, for future growth opportunities.</p>
<p>Stephanie Link of Hightower Advisors <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44716846/meta-ibm-palo-alto-networks-why-stephanie-link-doubling-down-tariff-proof-tech-titans">highlighted IBM</a> as a company in the software and services segment with recurring revenue and minimal exposure to global shocks given the current trade war climate.</p>
<p>Link highlighted IBM's low 1% exposure to reciprocal tariffs, compared to 43% for Apple and also said IBM's aggressive acquisition pace in areas like AI and cloud could help power future growth.</p>
<p><strong>Key Items to Watch</strong>: Artificial intelligence is likely to be a key topic when IBM reports its first-quarter results.</p>
<p>Analysts and investors will also be looking to hear more about the company's exposure to countries that are facing reciprocal tariffs from Donald Trump&#8217;s administration.</p>
<p>IBM's consulting and infrastructure segments saw a<a href="https://www.benzinga.com/25/01/43330515/ibm-stock-soars-8-in-premarket-after-beating-q4-beat-unveiling-ai-strategy"> weak fourth quarter</a> with revenue down year-over-year for both segments. Analysts and investors could be looking to see if these segments rebound in the first quarter.</p>
<p>Since the end of the fourth quarter, IBM has announced new products like the<a href="https://www.benzinga.com/tech/25/04/44696125/ibm-targets-real-time-ai-with-new-z17-mainframe-rollout"> IBM z17</a>, which blends AI features across software and hardware.</p>
<p>The z17 can address AI workloads and real-time processing needs for IBM customers. The product launches in June 2025.</p>
<p>IBM <a href="https://www.benzinga.com/25/04/44628415/ibm-boosts-canadian-ai-infrastructure-with-montreal-and-toronto-cloud-advances">also announced</a> it broadened its cloud offerings in Canada, which is part of a strategy to boost North American growth through AI-powered solutions.</p>
<p>"With our latest advancements in&nbsp;Canada, we are extending IBM's enterprise cloud platform and sovereign cloud capabilities to Canadian organizations in these sectors, helping them to address their local regulatory requirements, keeping data secured and maintain it in country," said GM for IBM Cloud Product &amp; Industry Platforms,&nbsp;<strong>Rohit Badlaney</strong>.</p>
<p>IBM also recently <a href="https://www.benzinga.com/news/large-cap/25/04/44669800/ibm-enhances-ai-consulting-muscle-with-hakkoda-deal">announced it has acquired</a> <strong>Hakkoda Inc</strong>, a deal that could enhance the company's consulting business segment for data transformation services.</p>
<p><strong>Price Action</strong>: IBM stock is up 3% to $248.10 on Wednesday versus a 52-week trading range of $162.62 to $266.45. IBM stock is up 12.8% year-to-date in 2025 and up over 36% in the last year.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43504732/ibm-story-is-underappreciated-goldman-sachs-says-stock-can-re-rate-higher">IBM Story Is Underappreciated, Goldman Sachs Says Stock Can Re-Rate Higher</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Previews

Tech

Trading Ideas

IBM Q1 Earnings Preview: AI, Acquisitions, New Products In Focus

<p>CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate CenterPoint Energy to report an <strong>earnings per share</strong> (EPS) of $0.55.</p>
<p>CenterPoint Energy bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 1.66% increase in the share price the following trading session.</p>
<p>Here's a look at CenterPoint Energy's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.4</td>
<td>0.32</td>
<td>0.33</td>
<td>0.53</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.4</td>
<td>0.31</td>
<td>0.36</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745420631_0.png" alt="eps graph" /></p>
<h3>Market Performance of CenterPoint Energy's Stock</h3>
<p>Shares of CenterPoint Energy were trading at $37.26 as of April 22. Over the last 52-week period, shares are up 27.13%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on CenterPoint Energy</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on CenterPoint Energy.</p>
<p>The consensus rating for CenterPoint Energy is Neutral, based on 7 analyst ratings. With an average one-year price target of $36.0, there's a potential 3.38% downside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of CMS Energy, Ameren and DTE Energy, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for CMS Energy, with an average 1-year price target of $77.71, suggesting a potential 108.56% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Ameren, with an average 1-year price target of $104.4, suggesting a potential 180.19% upside.</li>
<li>Analysts currently favor an Neutral trajectory for DTE Energy, with an average 1-year price target of $139.0, suggesting a potential 273.05% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for CMS Energy, Ameren and DTE Energy, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CenterPoint Energy</td>
<td>Neutral</td>
<td>3.67%</td>
<td>$976M</td>
<td>2.34%</td>
</tr>
<tr>
<td>CMS Energy</td>
<td>Outperform</td>
<td>2.00%</td>
<td>$877M</td>
<td>3.30%</td>
</tr>
<tr>
<td>Ameren</td>
<td>Neutral</td>
<td>19.96%</td>
<td>$794M</td>
<td>1.73%</td>
</tr>
<tr>
<td>DTE Energy</td>
<td>Neutral</td>
<td>1.24%</td>
<td>$1.15B</td>
<td>2.51%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>CenterPoint Energy ranks in the middle for consensus rating. It is at the bottom for revenue growth among peers. In terms of gross profit, it is at the top. For return on equity, it is in the middle compared to its peers.</p>
<h3>Get to Know CenterPoint Energy Better</h3>
<p>CenterPoint Energy owns a portfolio of businesses. Its regulated electric utilities provide transmission and distribution services to more than 2.5 million customers in the Houston area, southern Indiana, and west central Ohio. The company has natural gas distribution systems serving approximately 4 million customers.</p>
<h3>CenterPoint Energy: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining CenterPoint Energy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.67%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> CenterPoint Energy's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>10.96%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.34%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.57%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> CenterPoint Energy's debt-to-equity ratio is below the industry average. With a ratio of <b>1.97</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/CNP/earnings"><strong>To track all earnings releases for CenterPoint Energy visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: CenterPoint Energy's Earnings

<p>CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) is preparing to release its quarterly earnings on Thursday, 2025-04-24. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect CMS Energy to report an <strong>earnings per share</strong> (EPS) of $1.11.</p>
<p>CMS Energy bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 0.54% increase in the share price the following trading session.</p>
<p>Here's a look at CMS Energy's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.87</td>
<td>0.78</td>
<td>0.62</td>
<td>0.94</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.87</td>
<td>0.84</td>
<td>0.66</td>
<td>0.97</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-2.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745420619_0.png" alt="eps graph" /></p>
<h3>Performance of CMS Energy Shares</h3>
<p>Shares of CMS Energy were trading at $73.7 as of April 22. Over the last 52-week period, shares are up 21.31%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analysts' Take on CMS Energy</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on CMS Energy.</p>
<p>CMS Energy has received a total of 7 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $77.71, the consensus suggests a potential 5.44% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of CenterPoint Energy, NiSource and Ameren, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for CenterPoint Energy, with an average 1-year price target of $36.0, suggesting a potential 51.15% downside.</li>
<li>Analysts currently favor an Outperform trajectory for NiSource, with an average 1-year price target of $44.0, suggesting a potential 40.3% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Ameren, with an average 1-year price target of $104.4, suggesting a potential 41.66% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for CenterPoint Energy, NiSource and Ameren, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMS Energy</td>
<td>Outperform</td>
<td>2.00%</td>
<td>$877M</td>
<td>3.30%</td>
</tr>
<tr>
<td>CenterPoint Energy</td>
<td>Neutral</td>
<td>3.67%</td>
<td>$976M</td>
<td>2.34%</td>
</tr>
<tr>
<td>NiSource</td>
<td>Outperform</td>
<td>11.66%</td>
<td>$789.50M</td>
<td>2.61%</td>
</tr>
<tr>
<td>Ameren</td>
<td>Neutral</td>
<td>19.96%</td>
<td>$794M</td>
<td>1.73%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>CMS Energy is positioned in the middle among its peers for Consensus rating. It ranks at the bottom for Revenue Growth. In terms of Gross Profit, CMS Energy is at the top among its peers. However, for Return on Equity, it is positioned in the middle compared to its peers.</p>
<h3>Get to Know CMS Energy Better</h3>
<p>CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. NorthStar Clean Energy, formerly CMS Enterprises, is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.</p>
<h3>Unraveling the Financial Story of CMS Energy</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining CMS Energy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>2.0%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Utilities sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> CMS Energy's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>13.17%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CMS Energy's ROE excels beyond industry benchmarks, reaching <strong>3.3%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> CMS Energy's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.74%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> CMS Energy's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.07</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/CMS/earnings"><strong>To track all earnings releases for CMS Energy visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: CMS Energy's Earnings Forecast

The Future of Stem Cell Investing: Spotlight on Smaller Innovators

Markets

Press Releases

Mesoblast Added to S&P/ASX 200 INDEX

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Ryoncil® is Now Available for Purchase in the United States

Health Care

First Three Children to Commence Treatment With Ryoncil®

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Politics

Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

ADIA

BLUE

CRSP

FATE

MESO

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CareDx

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MiMedx Group

MannKind

Novavax

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Comments

Mesoblast

Mesoblast (MESO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO